Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.

"Declarations Consent for publicationNot applicable. Ethics approval and consent to participateThe Animal Welfare Committee of Stomatological Hospital of Tongji University approved all animal experimental protocols used in this study (NO.2020-DW-02). All mice were housed under standard laboratory conditions (12 h/12 h light/dark cycle and 22 ± 1℃) and accessible to food (ordinary solid food) and water freely. Furthermore, all methods are reported per the ARRIVE guidelines (https://arriveguidelines.org) for reporting animal experiments. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study was funded by Key Specialty Construction Project of Shanghai Pudong New Area Health Commission (Grant No. PWZzk2022-17); the Featured Clinical Discipline Project of Shanghai Pudong District (Grant No. PWYts2021-06); the Fund from Shanghai East Hospital (Grant No. DFLC2022019 and No. DFRC2018014)."